Clinical Trial Update: Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating masitinib with isoquercetin and best supportive care in hospitalized patients with moderate to severe COVID-19.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Disease 2019

Drugs mentioned

• Isoquercetin (isoquercetin)
• Masitinib (masitinib)

Snippet

Sponsor: AB Science | Conditions: SARS-CoV 2, COVID-19 | Phase 2 | Status: UNKNOWN